Antibody Discovery ADL specializes in advanced antibody discovery and display technologies including phage-display reagents and yeast-display. Their proprietary libraries ALTHEA Gold, Super Naive OPAL, MIM support end-to-end custom services (library construction, screening, expression, characterization). This positions ADL to partner with pharma/biotech R&D teams needing custom discovery pipelines and library resources.

Display Platforms ADL's growth from phage-display to yeast-display solutions creates cross-sell opportunities to researchers and CROs with varied display tech needs. Target teams evaluating multiple platforms, enabling ADL to win multi-platform engagements.

Strategic Partnerships Position ADL as a strategic partner to therapeutic and diagnostic researchers, leveraging end-to-end services to streamline vendor selection and project execution. Focus on collaborations with biotech startups and mid-sized firms to accelerate library adoption.

Cloning Edge FAST-Licase cloning system launched in 2017 provides a complementary workflow for clients requiring efficient cloning alongside library screening. Consider bundled offerings combining FAST-Licase with library discovery to increase deal value.

Growth Opportunity Lean team size and mid-range revenue suggest room to scale by offering larger-volume discovery services to CROs and biotech labs, as well as partnerships with larger service providers seeking niche, specialized capabilities.